The immunohistochemical assessment of HPV related adenocarcinoma: Pathologic and clinical prognostic significance

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1430-1438

  Balan, Raluca ^a   Cǎruntu, Irina Draga ^a   Amǎlinei, Cornelia ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adenosquamous carcinoma; Cervical adenocarcinoma; HPV; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; CAPSID PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTAGLANDIN SYNTHASE; PROTEIN P16; PROTEIN P53;

ARTICLE; CANCER RISK; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RISK ASSESSMENT; SCORING SYSTEM; UTERINE CERVIX CARCINOMA; UTERINE ENDOCERVIX; WART VIRUS;

EID: 84876734231     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804805496     Document Type: Article

References (58)

1. Zheng T, Holford TR, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 1996; 25: 252-8.
2. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000; 78: 97-105.
3. Wang HL, Lu DW. Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol 2004; 28: 901-8.
4. Witkiewicz AK, Wright TC, Ferenczy A, et al. Carcinoma and Other Tumors of the Cervix. In: Kurman RJ, Ellenson LH, Ronnett BM. Eds. Blaustein's Pathology of the Female Genital Tract. 6th ed. Springer Science-Business Media, LLC 2011; pp.273-303.
5. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000; 157: 1055-62.
6. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001; 37: 246-50.
7. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-15.
8. Kusanagi Y, Kojima A, Mikami Y, et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol 2010; 177: 2169-75.
9. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110: S18-S25.
10. Park KJ, Lamb C, Oliva E, Soslow RA, Kiyokawa T. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Mod Pathol 2008; 21: 217A.
11. Wu H, Shi H, Kong L. Relationship of HPVL1 and p16 expression with different cervical lesions. Sci Res Essays 2011; 6: 3724-8.
12. McCluggage WG, Jenkins D. P16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003; 22: 231-5.
13. Little L, Stewart CJR. Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Modern Pathol 2010; 23: 611-8.
14. Stewart CJR, Crook ML, Little L, Louwen K. Correlation between invasive pattern and immunophenotypic alterations in endocervical adenocarcinoma. Histopath 2011; 58: 720-8.
15. Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJM. Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer 2007; 121: 106-10.
16. Yoon HK, Kim YJ, Kang MS. Human Papillomavirus 16/18 expression of endocervical glandular lesions: relationship with p53 and MIB-1 expressions. J Korean Med Sci 2001; 16: 169-74.
17. McCluggage G, McBride H, Maxwell P, Bharucha H. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997; 16: 22-7.
18. Soonthornthum T, Arias-Pulido H, Joste N, et al. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2011; 22(10): 2166-78.
19. Iida K, Nakayama K, Rahman MT, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. British J Cancer 2011; 105: 420-7.
20. Baltazar F, Filho AL, Pinheiro C, et al. Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. Int J Gynecol Pathol 2007; 26: 235-41.
21. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7: 429-34.
22. Chen YJ, Wang LS, Wang PH, et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol 2003; 88: 379-85.
23. Griesser H, Sander H, Hilfrich R, Moser B, Schenck U. Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 2004; 26: 241-5.
24. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol 1998; 11: 155-68.
25. Leong AS. Quantitation in immunohistology: fact or fiction? A discussion of variables that influence results. Appl Immunohistochem Mol Morphol 2004; 12:1-7.
26. Yu L, Wang L, Zhong J, Chen S. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol 2010; 118: 47-55.
27. Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C. 16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003; 27: 187-93.
28. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol 2003; 22: 378-85.
29. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P. Utility of p16INK4a, CEA, Ki-67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol 2007; 26: 71-5.
30. Muller S, Flores-Staino C, Skyldberg B, et al. Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncol 2008; 32: 333-40.
31. Negri G, Bellisano G, Carico E, et al. Usefulness of p16ink4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri. Int J Gynecol Pathol 2011; 30: 407-13.
32. Fiedler M, Campo-Fernández B, Laich A, et al. Purification and characterisation of the E7 oncoproteins of the high-risk human papillomavirus types 16 and 18. J Virol Methods 2006; 134: 30-5.
33. Koo CL, Kok LF, Lee MY, et al. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Translat Med 2009; 7: 25.
34. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Löning T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002; 33: 899-904.
35. Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 2004; 445: 610-5.
36. Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J. p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens. Diagnostic Pathology 2009; 4: 22-8.
37. Negri G, Bellisano G, Zannoni GF, et al. p16ink4a and HPV L1 immunohistochemistry is helpful forestimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008; 32: 1715-20.
38. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32: S7-15.
39. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glanmdular lesions of the cervix. Mod Pathol 1997; 10: 176-80.
40. Dimitrakakis C, Kymionis G, Diakomanolis E, et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77: 129-36.
41. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002; 85: 469-75.
42. Saito T, Takehara M, Tanaka R, et al. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol 2004; 92: 284-92.
43. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papilloma virus and cervical cancer. J Clin pathol 2002; 55: 244-65.
44. Chapman WB, lorincz AT, Willet GD, et al. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. Int J gynecol Pathol 1992; 11: 221-26.
45. Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillomavirus e6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1271-76.
46. Akerman GS, Tolleson WH, Brown KL, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer res 2001; 61: 3837-43.
47. Zhang B, Srirangam A, Potter DA, Roman A. HPV 16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005; 24: 2585-88.
48. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor is associated with poor prognosis. Clin Cancer Res 1999; 5: 577-86.
49. Longatto-Filho A, Pinheiro C, Martinho O, et al. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer 2009; 9:212.
50. Del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008; 110: S72-S76.
51. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle 2006; 5: 2440-42.
52. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical nmeoplasia. Mod Pathol 1996; 9: 418-25.
53. Skomedal H, Kristensen GB, Lie AK, et al. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999; 73: 223-28.
54. Andl T, Khan T, Pfuhl A, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58: 5-13.
55. Li W, Thompson CH, Cossart YE, et al. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 2004; 26: 1-9.
56. Balan R, Simion N, Giusca SE, et al. Immunohistochemical assessment of p16, COX-2, and EGFR in HPV-positive cervical squamlous intraepithelial lesions. Rom J Morphol Embryol 2011; 52: 1187-94.
57. Chen TH, Fukuhara K, Mandai M, et al. Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas. Int J Gynecol Cancer 2006; 16: 772-79.
58. Melsheimer P, Kaul S, Dobeck S, Bastert G. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003; 47:124-28.